Glycogen synthase kinase 3b (GSK3b) reportedly has opposing roles, repressing Wnt/b-catenin signaling on the one hand but maintaining cell survival and proliferation through the NF-jB pathway on the other. The present investigation was undertaken to clarify the roles of GSK3b in human cancer. In colon cancer cell lines and colorectal cancer patients, levels of GSK3b expression and amounts of its active form were higher in tumor cells than in their normal counterparts; these findings were independent of nuclear accumulation of b-catenin oncoprotein in the tumor cells. Inhibition of GSK3b activity by phosphorylation was defective in colorectal cancers but preserved in non-neoplastic cells and tissues. Strikingly, inhibition of GSK3b activity by chemical inhibitors and its expression by RNA interference targeting GSK3b induced apoptosis and attenuated proliferation of colon cancer cells in vitro. Our findings demonstrate an unrecognized role of GSK3b in tumor cell survival and proliferation other than its predicted role as a tumor suppressor, and warrant proposing this kinase as a potential therapeutic target in colorectal cancer. Ó 2005 Elsevier Inc. All rights reserved.
Activation of the Wnt/b-catenin signaling pathway has emerged as an oncogenic pathway leading to colorectal cancer development [1, 2] . In an earlier study, we identified distinct patterns of b-catenin activation in human colorectal cancer and demonstrated that activation of this oncoprotein in the tumor invasion front reliably identifies a subset of colon cancer patients who are susceptible to tumor recurrence and have a less favorable survival rate [3] . These clinical observations establish the importance of molecular mechanism(s) underlying the distinct patterns of b-catenin activation. Among regulators of the Wnt signaling pathway [2] is glycogen synthase kinase 3b (GSK3b), which phosphorylates b-catenin, thereby recruiting it for ubiquitin-mediated degradation under physiological conditions [2, 4, 5] . Since GSK3b is a negative regulator of Wnt/b-catenin signaling, clarifying whether GSK3b plays a part in the mechanism underlying the different patterns of oncogenic b-catenin activation is a matter of considerable interest.
GSK3b is a multifunctional serine/threonine kinase that regulates various cellular pathways, depending on its substrates for phosphorylation [4] [5] [6] , and it is evident that regulation of Wnt/b-catenin signaling is only one of its diverse functions [4, 5] . Since oncogenic transcription factors (e.g., c-Jun, c-Myc) and proto-oncoproteins (i.e., b-catenin, Gli proteins) are putative GSK3b substrates for phosphorylation-dependent inactivation [4] , it is hypothesized that GSK3b interferes with cellular neoplastic transformation and tumor development, as exemplified by its activity in Wnt/b-catenin signaling [2] . However, only a few studies have addressed its role(s) in human cancer, and these studies have reported differing effects of GSK3b on cancer cells [7, 8] . Using GSK3b deficient mouse embryonic fibroblasts, it was shown that GSK3b plays a crucial role in cell survival mediated by the nuclear factor-jB (NF-jB) pathway [9, 10] . Interestingly, we have previously shown that the Wnt/b-catenin and NF-jB pathways were co-activated in colorectal cancer by dysregulation in the ubiquitin system [11] . Thus, these observations bring forward apparently opposing notions regarding the functions of GSK3b in neoplastic cells on the one hand, removing a neoplastic trigger by phosphorylation-dependent degradation of b-catenin oncoprotein in the ubiquitin system, and on the other, contributing to a cell proliferation and survival pathways by regulating NF-jB.
The present study was therefore undertaken to clarify the role of GSK3b in cancer by analyzing expression and activity of this kinase in colon cancer cell lines and clinical colorectal cancers and investigating its effects on cancer cells. Our results demonstrate that independently of its effects on Wnt/b-catenin signaling, GSK3b has a hitherto unrecognized pathologic role in cell survival and proliferation in colorectal cancer, and suggest the necessity of further studies to evaluate GSK3b as a potential therapeutic target for cancer treatment.
Materials and methods
Cell lines. Colon cancer cell lines (SW480, SW620, HT29, LoVo, HCT116, SW48, and RKO) and HEK293 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells of each type were grown and harvested for extraction of protein and DNA. Genetic alterations in all but one of the colon cancer cell lines have been documented (Table 1) [12] .
Patients and tissue samples. Subjects comprised 20 patients who underwent surgical removal of colorectal cancer in our institute in the period [2002] [2003] . Clinical data, tumor stage at initial treatment according to the TNM classification [13] , and presence of distant metastasis and recurrence are shown in Table 2 . All patients agreed to enrollment in the study and each gave informed consent. The Institutional Review Board of Kanazawa University approved all protocols upon patientsÕ agreement. A pair of normal and tumor tissue samples was obtained from each fresh surgical specimen and stored at À80°C until use.
In the light of evidence that nuclear accumulation (NA) of b-catenin is an indicator of oncogenic activity [2] , b-catenin activation in the primary tumor was determined by immunohistochemistry using the antibody to b-catenin (BD Biosciences) as described in our previous study [3] . Each instance of b-catenin expression in the primary tumor was classified into one of three distinct previously defined patterns [3] : membranous expression (M), imitating that found in normal crypts; diffuse NA (NAd), defined as carcinoma cells with b-catenin-positive nuclei distributed throughout the tumor; and NA only in the tumor invasion front (NAinv).
Western blotting analysis. Cellular protein was extracted from frozen surgical specimens and cell lines using lysis buffer (CelLytic-MT, SigmaAldrich, St. Louis, MO) in a mixture of protease and phosphatase inhibitors (both from Sigma-Aldrich). A 100 lg aliquot of protein extract was subjected to Western blotting analysis as described previously [11] to examine expression of the respective kinases using primary antibodies against GSK3b (diluted 1:2,500; BD Biosciences, Lexington, KY) and its fractions phosphorylated at the serine 9 residue (phosphoGSK3b Ser9 ) (diluted 1:1,000; Cell Signaling Technology, Beverly, MA), and the tyrosine 216 (phospho-GSK3b Tyr216 ) (diluted 1:1,000; BD Biosciences), respectively. As a representative of activated kinases upstream to GSK3b, protein kinase B (PKB, also termed Akt) activity was determined by immunoblotting with antibodies to phospho-Akt Thr308 and phospho-Akt Ser473 (both diluted 1:1,000) (Cell Signaling Technology). In each case, signals were developed using an enhanced chemiluminescent detection reagent (ECL, Amersham, Little Chalfont, UK).
In vitro kinase assay. GSK3b was immunoprecipitated from the cell lines and subjected to an in vitro kinase assay using a recombinant human b-catenin protein (generated in our laboratory) as a substrate according to the method described previously [14] . The phosphorylated fraction of b-catenin was detected by autoradiography. 
Abbreviations: F, female; M, male; A, ascending colon; C, cecum; R, rectum; S, sigmoid colon; Tr, transverse colon; N, non-neoplastic mucosa tissue; T, primary tumor; NE, not evident; À, absent; +, present; NAd, diffuse pattern of b-catenin activation in tumor; NAinv, b-catenin activation in tumor cells forming the invasion front. a Metastasis/recurrence: Follow-up examination after surgery disclosed metastasis to distant organs in four patients. b K-ras mutation: 12, mutation in codon 12; 13, mutation in codon 13.
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Cytochemical and immunocytochemical staining. Cell lines grown on glass coverslips were subjected to immunofluorescence staining [15] to detect whole GSK3b and phospho-GSK3b
Ser9 with the same primary antibodies (diluted 1:100) used for immunoblotting, respectively. Cy3-labeled goat anti-mouse IgG (H + L) and FITC-labeled goat anti-rabbit IgG (H + L) (Jackson ImmunoResearch, Baltimore, MD) were diluted 1:200, respectively, to detect whole GSK3b and phosphoGSK3b
Ser9
. Nuclei were counterstained with Hoechst 33342. The stained cells were observed under a fluorescence microscope (Olympus AX80, Tokyo, Japan) connected to a CCD digital camera (Olympus DP70).
Detection of mutations in GSK3b Ser9 and K-ras genes. Genomic DNA was extracted from colon cancer cell lines and pairs of normal and tumor tissues from surgical specimens by proteinase K digestion and treatment with phenol and chloroform. Exon 1 of the GSK3b gene was PCR-amplified (94°C for 1 min, 55°C for 1 min, and 72°C for 1 min for 35 cycles) with a set of upstream primer 5 0 -ATTCGCGAAG AGAGTGATCAT-3 0 and downstream primer 5 0 -CACTGCTAAC TTTCATGCTGC-3 0 . Mutation in GSK3b codon 9 (TCC) was analyzed by restriction fragment length polymorphism (PCR-RFLP) analysis using MnlI (NEB, Beverly, MA), which cleaves a 110 base pair PCR product with wild-type codon 9 into two fragments of 52 and 58 base pairs but does not cleave a PCR product with any mutation in codon 9. Mutations in codons 12 and 13 of the K-ras gene were detected by mismatched primers-mediated PCR-RFLP analysis, as described in our previous report [3] .
Treatment with GSK3b inhibitors. HEK293 and colon cancer cells seeded in a 96-well plate were treated with dimethyl sulfoxide (DMSO), or AR-A014418 (Calbiochem, San Diego, CA) and SB-216763 (Sigma-Aldrich), both known GSK3b inhibitors [16, 17] dissolved in DMSO at the indicated concentrations. At designated times (24, 48, 72 , and 96 h), relative numbers of viable cells were determined by measuring the optical density using a WST-8 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) assay kit (Cell Counting Kit-8, Wako, Osaka, Japan) by means of spectrophotometry using a microtiter-plate reader (Bio-Rad, Hercules, CA). The results were expressed as the mean optical density and standard deviations of the 6-well set for each AR-A014418 or SB-216763 dose.
RNA interference. Small interfering RNA (siRNA) specific to human GSK3b and negative control siRNA were purchased from Dharmacon (Lafayette, CO). The effect of siRNA transfection was optimized using TransIT-TKO Transfection Reagent (Mirus, Madison, WI) according to the manufacturerÕs protocol. The effect of siRNA on GSK3b expression was observed using Western blotting with an antibody that binds to both GSK3a and GSK3b (diluted 1:1,000; Upstate Biotechnology, Lake Placid, NY). At the optimal concentration, the effects of GSK3b siRNA transfection on cell viability at the designated times were investigated as described above.
Apoptosis and cell proliferation assays. Influences of the inhibitors and siRNA specific to GSK3b on cells were analyzed to determine changes in apoptosis and cell proliferation. After treatment with the GSK3b inhibitors, siRNA and their control reagents as described above, cells were immunostained with the antibody to proliferating cell nuclear antigen (PCNA; DakoCytomation, Glostrup, Denmark) to label proliferating cells and counterstained with Hoechst to detect apoptotic cells characterized by discrete fragmentation of nuclei. A total of 200 nuclei per field was counted and scored for apoptosis changes and PCNA-positive nuclei, respectively. The mean scores for apoptosis and PCNA-positive nuclei in all five fields were then calculated.
Results and discussion

Expression and activity of GSK3b in colorectal cancer
All colon cancer cells showed higher basal levels of GSK3b and its active form phospho-GSK3b
Tyr216 , and no detectable phospho-GSK3b Ser9 (inactive form) than HEK293 cells in Western blotting analysis (Fig. 1A ). An in vitro kinase assay demonstrated that GSK3b isolated from these cell lines phosphorylated b-catenin protein (Fig. 1B) . In contrast to the findings in colon cancer cells, phospho-GSK3b
Ser9 was detected in HEK293 cells, where we previously showed physiological regulation of a steady-state low level of b-catenin expression [11] . Immunocytochemically, GSK3b was localized in the cytoplasm of all cell lines analyzed, and phospho-GSK3b
Ser9 was detected only in HEK293 cells (Fig. 2) . The results indicated that high levels of GSK3b expression and activity were characteristic of all colon cancer cells where b-catenin was activated either ) were determined by Western blotting in colon cancer cell lines. The protein extract from a lymphocyte cell line, Jurkat (J), was used as a positive control for detection of phospho-Akt Thr308 and phospho-Akt Ser473 , according to the manufacturerÕs directions for the antibodies to Akt and phosphoAkt. Results of these analyses are described in Table 1. by mutations in APC (SW480, SW620, and LoVo) or CTNNB1 (b-catenin gene) (HCT116, SW48) ( Table 1) .
Levels of GSK3b and the two phosphorylated forms were analyzed in pairs of normal and tumor tissues of colorectal cancer patients (Fig. 3) . The levels of GSK3b and its active form phospho-GSK3b
Tyr216 in the tumors were higher than in their normal counterparts in most cases. On the contrary, the inactive form phosphoGSK3b
Ser9 was frequently detected in high levels in non-neoplastic tissues, but tumors in most cases con-
GSK3β pGSK3β
Ser9
GSK3β pGSK3β
Ser9 +Hoechst +Hoechst +Hoechst +Hoechst SW480 Fig. 2 . Double immunofluorescence cytochemical staining of total GSK3b (probed with Cy3-labeled secondary antibody, red fluorescence) and phospho-GSK3b Ser9 (probed with FITC-labeled secondary antibody, green fluorescence) in HEK293 cells (upper four panels) and SW480 colon cancer cells (lower four panels). Nuclei were counterstained with Hoechst 33342 (blue fluorescence) and merged with respective fluorescent microscopic images for total GSK3b and phospho-GSK3b
Ser9 (indicated as +Hoechst). The expression intensity of total GSK3b in cytoplasm was higher in SW480 than in HEK293 cells. Phospho-GSK3b
Ser9 was found in the cytoplasm of HEK293 but not SW480 cells. The scale bar in each panel indicates 100 lm. All images in a gallery have the same magnification. tained only trace amounts or no detectable level of this form (Table 2 ). In light of the in vitro kinase assay referred to above, the major fraction of GSK3b in the tumor was considered active. b-Catenin activation was detected in the tumors of 13 (65%) patients-7 with the NAd pattern and 6 with the NAinv pattern. Similar to the observations in colon cancer cell lines, expression and activity of GSK3b in colorectal tumors showed no particular association with the presence or pattern of b-catenin activation (Table 2) .
In contrast to the postulated function of GSK3b as a negative regulator of Wnt/b-catenin signaling [2, 4] , GSK3b is constitutively active and phosphorylation-dependent inhibition of its activity was defective in most colorectal cancers analyzed in the present study. It is well documented that the basal level of GSK3b activity in cells is normally high and that its physiological activity is maintained by inhibitory serine 9 phosphorylation of this kinase initiated by diverse stimuli [4] [5] [6] . The presence of an inactive form, phospho-GSK3b
Ser9 , in HEK293 cells and normal tissues demonstrated here suggests a regulation of balanced expression of active and inactive forms of this kinase. Paradoxically, absence of phospho-GSK3b
Ser9 in the tumors implies that expression and activity of GSK3b in colorectal cancer are no longer regulated physiologically, indicating that such expression and activity represent one of the biological characteristics of neoplastic cells as discussed below, and thus reflect a potentially non-physiological role for this kinase in colorectal cancer.
The first recognized function of GSK3b is to phosphorylate and inhibit glycogen synthase activity, resulting in a relative increase of glucose metabolism [4] [5] [6] . It is well known that tumors consistently rely on anaerobic pathways to convert glucose to ATP even in the presence of abundant oxygen, and that tumor cells maintain ATP production by increasing glucose influx to fuel the energy requirements of unrestricted proliferation [18] . The upregulation of active GSK3b in most colorectal cancers shown here may contribute to high consumption of glucose by cancer cells through inhibition of glycogen synthesis.
The expression level or activity of GSK3b is not a determinant of the pattern (i.e., NAd and NAinv) of b-catenin activation in the tumors of colorectal cancer patients. This is partly in line with a report showing that no b-catenin accumulation was found in tissues of GSK3b-knockout mice [9] . Importantly, it in turn indicates that GSK3b may play a role in colorectal cancer other than its predicted role [4] [5] [6] as a tumor suppressor. There was no association between expression and activity of GSK3b and any clinical characteristics of colorectal cancer patients, including tumor stage and occurrence of metastasis (Table 2 ). These findings suggest that GSK3b may participate in colorectal cancer development through a pathway independent of Wnt signaling. Table 2 . In most patients, levels of total GSK3b and its active form phospho-GSK3b
Tyr216 in the primary tumors were higher than in corresponding normal tissues. Whereas the inactive form phospho-GSK3b
Ser9 was frequently detected in non-neoplastic tissues, the primary tumors in most cases (other than patients No. 74 and 79) had trace or undetectable levels of the inactive form. As described in Table 2 , expression of GSK3b or presence of phospho-GSK3b
Ser9 or phospho-GSK3b Tyr216 was not correlated with presence or different patterns of b-catenin activation in the tumors.
Putative upstream events in GSK3b activity
We next addressed possible upstream event(s) regulating expression or phosphorylation-dependent inactivation of GSK3b in colorectal cancer. The best characterized upstream kinase that inactivates GSK3b is PKB/Akt [19] , which is known to be activated by phosphoinositide 3-kinase (PI3K)-dependent phosphorylation [20] . PI3K activation is downstream of both insulin [20] and ras signaling [21] , and the latter signaling pathway is frequently accelerated by mutational activation of K-ras in colorectal cancer [21] . In view of these signaling network considerations, we analyzed active forms of PKB/Akt (phospho-Akt Thr308 and phospho-Akt Ser473 ) (Fig. 1C) and mutations in the K-ras gene, and investigated whether either factor influences expression of GSK3b and its activity, as estimated on the basis of presence of the two phosphorylated forms. As shown in Tables 1 and 2 , there was no correlation between GSK3b activity and PKB/Akt phosphorylation or mutational activation of K-ras in the colon cancer cell lines and 20 colorectal cancers (Fig. 1C, supplementary Fig. 1) . The results suggest that upstream factors or mechanisms yet unknown, other than signaling mediated by the Ras or PKB/Akt pathway, increase the level of GSK3b or prevent its inactivation in colorectal cancer.
It has been reported that a mutation generated in codon 9 of the GSK3b gene, which prevents phosphorylation-dependent inactivation, results in constitutive activation of this kinase [22] . Although this would be an alternative mechanism that increases GSK3b activity, no mutation was detected in GSK3b gene codon 9 in colon cancer cell lines or clinical colorectal cancers (data not shown). Thus, a mutation that inhibits Ser 9 phosphorylation is not a putative mechanism for increased activity of GSK3b in colorectal cancer.
Inhibition of GSK3b expression and activity attenuates cell survival and proliferation and induces apoptosis
In view of our data showing that GSK3b is overexpressed and active in colorectal cancer, it is important to ascertain the functional role of this kinase in this type tumor. Therefore, we assessed the effects of inhibition of GSK3b activity and down-regulation of its expression on viability and proliferation of colon cancer cells in vitro. When colon cancer cell lines were treated with various concentrations of the GSK3b inhibitors AR-A014418 or SB-216763 [16, 17] , cell viability was reduced in a dose-dependent manner (Figs. 4A and B,  supplementary Fig. 2 ). This effect was associated with increased apoptosis and a decreased fraction of proliferating cells labeled by PCNA (Figs. 4C and D) . However, no or little effect of these inhibitors on cell survival rate or apoptosis was found in HEK293 cells (Fig. 4) . It is of interest whether these pharmacological inhibitors alter expression and phosphorylation of GSK3b in colon cancer cells. Levels of expression and phosphorylation at Ser9 or Tyr216 of GSK3b were monitored in colon cancer cells (SW480 and HCT116) at the different time points (24 and 48 h) after treatment with different doses (25 and 50 lM) of each inhibitor or DMSO. As represented in Supplementary Fig. 3 , no alteration was found in the level of expression or amounts of the phosphorylated forms of GSK3b after treatment with GSK3b inhibitors. This finding is consistent with the reported mechanism of action of most pharmacological GSK3b inhibitors that act by competing with ATP in the ATP-binding site of the kinase [17] . In order to validate the effects of the GSK3 inhibitors on colorectal cancer cell proliferation and survival, we genetically depleted GSK3b using RNA interference (RNAi). Transfecting siRNA mixtures (25 nM each) specific to GSK3b decreased only the expression of GSK3b, but not the closely related GSK3a isoform, in the cells examined (Fig. 5A, supplementary Fig. 4) . Strikingly, depletion of GSK3b in colon cancer cells, but not HEK293 cells, lead to decreased cell viability and an increase in apoptosis, (Figs. 5A and B, supplementary Fig. 4) . Furthermore, knockdown of this kinase by RNAi decreased PCNA-positive cells, indicating inhibition of tumor cell proliferation (Fig. 5C ). These results together indicate that both activity and expression of GSK3b are prerequisite to colorectal tumor cell survival and proliferation, thereby reflecting a potential pathologic role of this kinase in colorectal cancer.
The pathways that use GSK3b as a key regulator have been implicated in the development of human diseases other than cancer [5, 16] . One such disease is noninsulin-dependent (type 2) diabetes mellitus (NIDDM), which is frequently associated with increased GSK3b activity [5, 16] . The latter observation is in line with a reported association between NIDDM or insulin-resistance and risk of developing colorectal cancer [23, 24] . Many studies link activation of GSK3b and neuropsychiatric disorders, exemplified by AlzheimerÕs disease, on the basis of GSK3b-mediated phosphorylation of tau, one of the hallmarks of this disease (reviewed in [16, 25] ). Interestingly, it is reported that risk of cancer development in psychiatric patients treated with lithium carbonate, a GSK3b inhibitor used for bipolar disorder [5] , is significantly lower than in the general population, and that an inverse relationship has been observed between cancer morbidity and lithium dosage [26] .
A number of GSK3b inhibitors have been generated primarily for development of new drugs for treatment of NIDDM and AlzheimerÕs disease [16, 17] , but never for treatment of neoplastic diseases [16] . In this study, however, we showed that either inhibition of GSKb activity or down-regulation of its expression reduced the cell viability and proliferation and increased frequency of apoptosis in colon cancer cells. In this connection, it has been shown that GSK3b plays a role in cell survival by phosphorylating the p65 subunit of NF-jB in hepatocytes [9, 10] . Moreover, a recent study [27] has demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs), the known cancer chemopreventive agents, induced phosphorylation of both b-catenin and GSK3b (serine 9 residue) prior to down-regulation of b-catenin/ Tcf signaling. Taken together, our results and these considerations suggest that GSK3b could be a potential target for treatment and prevention of colorectal cancer. In addition, whether GSK3b is regulating NF-jB activity in colorectal cancer cells remains to be determined. In all, our study demonstrates a previously unrecognized pathologic role of GSK3b in colorectal cancer, both by substantiating its activity in established colon cancer cells and clinical colorectal cancers and by pharmacologically and genetically modulating the activity and expression of this kinase in cancer cells. In addition to its promoting effect on cell survival and proliferation, GSK3b regulates a wide range of cellular processes including energy metabolism, transcription control, and cell fate determination, by modulating cellular regulatory proteins and transcription factors [4] [5] [6] . Therefore, investigating broader mechanisms underlying a potential oncogenic role of GSK3b may provide insights into molecular pathways leading to colorectal tumorigenesis, and support development of novel strategies for treatment and chemoprevention targeting this kinase and the molecular epidemiology of colorectal cancer.
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